{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T13:11:40Z","timestamp":1791983500546,"version":"4.4.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T00:00:00Z","timestamp":1641859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T00:00:00Z","timestamp":1641859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["5RO1 CA200795"],"award-info":[{"award-number":["5RO1 CA200795"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s10549-021-06503-1","type":"journal-article","created":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T14:03:41Z","timestamp":1641909821000},"page":"321-329","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["The progesterone-receptor modulator, ulipristal acetate, drastically lowers breast cell proliferation"],"prefix":"10.1007","volume":"192","clinical-trial-number":[{"clinical-trial-number":"nct02922127","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3622-8846","authenticated-orcid":false,"given":"Carolyn L.","family":"Westhoff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanina","family":"Hibshoosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Polaneczky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm C.","family":"Pike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,11]]},"reference":[{"issue":"9","key":"6503_CR1","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1001\/jama.2019.11885","volume":"322","author":"DK Owens","year":"2019","unstructured":"Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M et al (2019) Medication use to reduce risk of breast cancer: US preventive services task force recommendation statement. JAMA 322(9):857\u2013867. https:\/\/doi.org\/10.1001\/jama.2019.11885","journal-title":"JAMA"},{"issue":"1","key":"6503_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1093\/oxfordjournals.epirev.a036102","volume":"15","author":"MC Pike","year":"1993","unstructured":"Pike MC, Spicer DV, Dahmoush L, Press MF (1993) Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 15(1):17\u201335. https:\/\/doi.org\/10.1093\/oxfordjournals.epirev.a036102","journal-title":"Epidemiol Rev"},{"issue":"5","key":"6503_CR3","first-page":"1441","volume":"47","author":"S Bardon","year":"1987","unstructured":"Bardon S, Vignon F, Montcourrier P, Rochefort H (1987) Steroid receptor-mediated cytotoxicity of an antiestrogen and an antiprogestin in breast cancer cells. Cancer Res 47(5):1441\u20131448","journal-title":"Cancer Res"},{"issue":"14","key":"6503_CR4","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1517\/14656566.9.14.2487","volume":"9","author":"G Benagiano","year":"2008","unstructured":"Benagiano G, Bastianelli C, Farris M (2008) Selective progesterone receptor modulators 3: use in oncology, endocrinology and psychiatry. Expert Opin Pharmacother 9(14):2487\u20132496. https:\/\/doi.org\/10.1517\/14656566.9.14.2487","journal-title":"Expert Opin Pharmacother"},{"issue":"10\u201311","key":"6503_CR5","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/s0039-128x(00)00189-6","volume":"65","author":"HJ Kloosterboer","year":"2000","unstructured":"Kloosterboer HJ, Deckers GH, Schoonen WG, Hanssen RG, Rose UM, Verbost PM et al (2000) Preclinical experience with two selective progesterone receptor modulators on breast and endometrium. Steroids 65(10\u201311):733\u2013740. https:\/\/doi.org\/10.1016\/s0039-128x(00)00189-6","journal-title":"Steroids"},{"issue":"1","key":"6503_CR6","first-page":"167","volume":"18","author":"RD Wiehle","year":"2007","unstructured":"Wiehle RD, Christov K, Mehta R (2007) Anti-progestins suppress the growth of established tumors induced by 7,12-dimethylbenz(a)anthracene: comparison between RU486 and a new 21-substituted-19-nor-progestin. Oncol Rep 18(1):167\u2013174","journal-title":"Oncol Rep"},{"issue":"9","key":"6503_CR7","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1093\/humrep\/den228","volume":"23","author":"M Engman","year":"2008","unstructured":"Engman M, Skoog L, Soderqvist G, Gemzell-Danielsson K (2008) The effect of mifepristone on breast cell proliferation in premenopausal women evaluated through fine needle aspiration cytology. Hum Reprod 23(9):2072\u20132079. https:\/\/doi.org\/10.1093\/humrep\/den228","journal-title":"Hum Reprod"},{"issue":"10\u201313","key":"6503_CR8","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.steroids.2003.07.002","volume":"68","author":"DT Baird","year":"2003","unstructured":"Baird DT, Brown A, Cheng L, Critchley HO, Lin S, Narvekar N, Williams AR (2003) Mifepristone: a novel estrogen-free daily contraceptive pill. Steroids 68(10\u201313):1099\u20131105. https:\/\/doi.org\/10.1016\/j.steroids.2003.07.002","journal-title":"Steroids"},{"issue":"9","key":"6503_CR9","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1093\/humrep\/dem177","volume":"22","author":"F Lakha","year":"2007","unstructured":"Lakha F, Ho PC, Van der Spuy ZM, Dada K, Elton R, Glasier AF et al (2007) A novel estrogen-free oral contraceptive pill for women: multicentre, double-blind, randomized controlled trial of mifepristone and progestogen-only pill (levonorgestrel). Hum Reprod 22(9):2428\u20132436. https:\/\/doi.org\/10.1093\/humrep\/dem177","journal-title":"Hum Reprod"},{"issue":"1\u20132","key":"6503_CR10","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/s0303-7207(01)00743-2","volume":"188","author":"BJ Attardi","year":"2002","unstructured":"Attardi BJ, Burgenson J, Hild SA, Reel JR, Blye RP (2002) CDB-4124 and its putative monodemethylated metabolite, CDB-4453, are potent antiprogestins with reduced antiglucocorticoid activity: in vitro comparison to mifepristone and CDB-2914. Mol Cell Endocrinol 188(1\u20132):111\u2013123. https:\/\/doi.org\/10.1016\/s0303-7207(01)00743-2","journal-title":"Mol Cell Endocrinol"},{"issue":"5","key":"6503_CR11","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1056\/NEJMoa1103182","volume":"366","author":"J Donnez","year":"2012","unstructured":"Donnez J, Tatarchuk TF, Bouchard P, Puscasiu L, Zakharenko NF, Ivanova T et al (2012) Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med 366(5):409\u2013420. https:\/\/doi.org\/10.1056\/NEJMoa1103182","journal-title":"N Engl J Med"},{"issue":"6","key":"6503_CR12","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/j.fertnstert.2014.02.008","volume":"101","author":"J Donnez","year":"2014","unstructured":"Donnez J, Vazquez F, Tomaszewski J, Nouri K, Bouchard P, Fauser BC et al (2014) Long-term treatment of uterine fibroids with ulipristal acetate. Fertil Steril 101(6):1565\u20131573. https:\/\/doi.org\/10.1016\/j.fertnstert.2014.02.008","journal-title":"Fertil Steril"},{"issue":"9714","key":"6503_CR13","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0140-6736(10)60101-8","volume":"375","author":"AF Glasier","year":"2010","unstructured":"Glasier AF, Cameron ST, Fine PM, Logan SJ, Casale W, Van Horn J et al (2010) Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis. Lancet 375(9714):555\u2013562. https:\/\/doi.org\/10.1016\/S0140-6736(10)60101-8","journal-title":"Lancet"},{"issue":"9","key":"6503_CR14","doi-asserted-by":"publisher","first-page":"3582","DOI":"10.1210\/jc.2006-2816","volume":"92","author":"N Chabbert-Buffet","year":"2007","unstructured":"Chabbert-Buffet N, Pintiaux-Kairis A, Bouchard P, Group VAS (2007) Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic-pituitary-ovarian axis and endometrium in normal women: a prospective, randomized, placebo-controlled trial. J Clin Endocrinol Metab 92(9):3582\u20133589. https:\/\/doi.org\/10.1210\/jc.2006-2816","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"6503_CR15","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s12672-016-0255-4","volume":"7","author":"N Esber","year":"2016","unstructured":"Esber N, Cherbonnier C, Resche-Rigon M, Hamze A, Alami M, Fagart J et al (2016) Anti-tumoral effects of anti-progestins in a patient-derived breast cancer xenograft model. Horm Cancer 7(2):137\u2013147. https:\/\/doi.org\/10.1007\/s12672-016-0255-4","journal-title":"Horm Cancer"},{"issue":"2","key":"6503_CR16","first-page":"231","volume":"55","author":"SR Wellings","year":"1975","unstructured":"Wellings SR, Jensen HM, Marcum RG (1975) An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions. J Natl Cancer Inst 55(2):231\u2013273","journal-title":"J Natl Cancer Inst"},{"key":"6503_CR17","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/BF01806214","volume":"40","author":"H Olsson","year":"1996","unstructured":"Olsson H, Jernstrom H, Alm P, Ingvar C, Jonsson P-E, Ryden S (1996) Proliferation of the breast epithelium in relation to menstrual cycle phase, hormone use, and reproductive factors. Breast Cancer Res Treat 40:187\u2013196. https:\/\/doi.org\/10.1007\/BF01806214","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"6503_CR18","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/s0002-9378(97)80024-5","volume":"176","author":"G S\u00f6derqvist","year":"1997","unstructured":"S\u00f6derqvist G, Isaksson E, von Schoultz B, Carlstrom K, Tani E, Skoog L (1997) Proliferation of breast epithelial cells in healthy women during the menstrual cycle. Am J Obstet Gynecol 176(1):123\u2013128. https:\/\/doi.org\/10.1016\/s0002-9378(97)80024-5","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"6503_CR19","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1023\/a:1006482418082","volume":"65","author":"E Isaksson","year":"2001","unstructured":"Isaksson E, Schoultz Ev, Odlind V, S\u00f6derqvist G, Csemiczky G, Carlstr\u00f6m K et al (2001) Effects of oral contraceptives on breast epithelial proliferation. Breast Cancer Res Treat 65(2):163\u2013169. https:\/\/doi.org\/10.1023\/a:1006482418082","journal-title":"Breast Cancer Res Treat"},{"issue":"9017","key":"6503_CR20","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/s0140-6736(96)90806-5","volume":"347","author":"Collaborative Group on Hormonal Factors in Breast Cancer","year":"1996","unstructured":"Collaborative Group on Hormonal Factors in Breast Cancer (1996) Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 347(9017):1713\u20131727. https:\/\/doi.org\/10.1016\/s0140-6736(96)90806-5","journal-title":"Lancet"},{"issue":"2","key":"6503_CR21","doi-asserted-by":"publisher","first-page":"169.e1","DOI":"10.1016\/j.ajog.2018.03.032","volume":"219","author":"CL Westhoff","year":"2018","unstructured":"Westhoff CL, Pike MC (2018) Hormonal contraception and breast cancer. Am J Obstet Gynecol 219(2):169.e1-169.e4. https:\/\/doi.org\/10.1016\/j.ajog.2018.03.032","journal-title":"Am J Obstet Gynecol"},{"issue":"11","key":"6503_CR22","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1038\/sj.bjc.6602617","volume":"92","author":"SA Lee","year":"2005","unstructured":"Lee SA, Ross RK, Pike MC (2005) An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk. Br J Cancer 92(11):2049\u20132058. https:\/\/doi.org\/10.1038\/sj.bjc.6602617","journal-title":"Br J Cancer"},{"issue":"10","key":"6503_CR23","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1158\/1055-9965.EPI-10-0747","volume":"19","author":"DJ Hunter","year":"2010","unstructured":"Hunter DJ, Colditz GA, Hankinson SE, Malspeis S, Spiegelman D, Chen W et al (2010) Oral contraceptive use and breast cancer: a prospective study of young women. Cancer Epidemiol Biomark Prev 19(10):2496\u20132502. https:\/\/doi.org\/10.1158\/1055-9965.EPI-10-0747","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"3","key":"6503_CR24","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.contraception.2011.12.015","volume":"86","author":"L Hovanessian-Larsen","year":"2012","unstructured":"Hovanessian-Larsen L, Taylor D, Hawes D, Spicer DV, Press MF, Wu AH et al (2012) Lowering oral contraceptive norethindrone dose increases estrogen and progesterone receptor levels with no reduction in proliferation of breast epithelium: a randomized trial. Contraception 86(3):238\u2013243. https:\/\/doi.org\/10.1016\/j.contraception.2011.12.015","journal-title":"Contraception"},{"issue":"2","key":"6503_CR25","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s10549-018-4916-6","volume":"172","author":"JS Sung","year":"2018","unstructured":"Sung JS, Corben AD, Brooks JD, Edelweiss M, Keating DM, Lin C et al (2018) Histopathologic characteristics of background parenchymal enhancement (BPE) on breast MRI. Breast Cancer Res Treat 172(2):487\u2013496. https:\/\/doi.org\/10.1007\/s10549-018-4916-6","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"6503_CR26","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1002\/jmri.25798","volume":"47","author":"E Mema","year":"2018","unstructured":"Mema E, Mango VL, Guo X, Karcich J, Yeh R, Wynn RT et al (2018) Does breast MRI background parenchymal enhancement indicate metabolic activity? Qualitative and 3D quantitative computer imaging analysis. J Magn Reson Imaging 47(3):753\u2013759. https:\/\/doi.org\/10.1002\/jmri.25798","journal-title":"J Magn Reson Imaging"},{"issue":"12","key":"6503_CR27","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1007\/s00330-012-2553-8","volume":"22","author":"V King","year":"2012","unstructured":"King V, Gu Y, Kaplan JB, Brooks JD, Pike MC, Morris EA (2012) Impact of menopausal status on background parenchymal enhancement and fibroglandular tissue on breast MRI. Eur Radiol 22(12):2641\u20132647. https:\/\/doi.org\/10.1007\/s00330-012-2553-8","journal-title":"Eur Radiol"},{"issue":"6","key":"6503_CR28","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/tbj.12002","volume":"18","author":"V King","year":"2012","unstructured":"King V, Kaplan J, Pike MC, Liberman L, David Dershaw D, Lee CH et al (2012) Impact of tamoxifen on amount of fibroglandular tissue, background parenchymal enhancement, and cysts on breast magnetic resonance imaging. Breast J 18(6):527\u2013534. https:\/\/doi.org\/10.1111\/tbj.12002","journal-title":"Breast J"},{"issue":"3","key":"6503_CR29","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1148\/radiol.12112669","volume":"264","author":"V King","year":"2012","unstructured":"King V, Goldfarb SB, Brooks JD, Sung JS, Nulsen BF, Jozefara JE et al (2012) Effect of aromatase inhibitors on background parenchymal enhancement and amount of fibroglandular tissue at breast MR imaging. Radiology 264(3):670\u2013678. https:\/\/doi.org\/10.1148\/radiol.12112669","journal-title":"Radiology"},{"issue":"4","key":"6503_CR30","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.fertnstert.2018\/.06.044","volume":"110","author":"J Donnez","year":"2018","unstructured":"Donnez J (2018) Liver injury and ulipristal acetate: an overstated tragedy? Fertil Steril 110(4):593\u2013595. https:\/\/doi.org\/10.1016\/j.fertnstert.2018\/.06.044","journal-title":"Fertil Steril"},{"issue":"3","key":"6503_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6503a1","volume":"65","author":"KM Curtis","year":"2016","unstructured":"Curtis KM, Tepper NK, Jatlaoui TC, Berry-Bibee E, Horton LG, Zapata LB et al (2016) U.S. medical eligibility criteria for contraceptive use, 2016. MMWR Recomm Rep 65(3):1\u2013103. https:\/\/doi.org\/10.15585\/mmwr.rr6503a1","journal-title":"MMWR Recomm Rep"},{"issue":"5","key":"6503_CR32","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1067\/j.cpradiol.2016.02.003","volume":"45","author":"R Ha","year":"2016","unstructured":"Ha R, Mema E, Guo X, Mango V, Desperito E, Ha J et al (2016) Three-dimensional quantitative validation of breast magnetic resonance imaging background parenchymal enhancement assessments. Curr Probl Diagn Radiol 45(5):297\u2013303. https:\/\/doi.org\/10.1067\/j.cpradiol.2016.02.003","journal-title":"Curr Probl Diagn Radiol"},{"issue":"1","key":"6503_CR33","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.mric.2009.09.005","volume":"18","author":"EA Morris","year":"2010","unstructured":"Morris EA (2010) Diagnostic breast MR imaging: current status and future directions. Magn Reson Imaging Clin N Am 18(1):57\u201374. https:\/\/doi.org\/10.1016\/j.mric.2009.09.005","journal-title":"Magn Reson Imaging Clin N Am"},{"issue":"5","key":"6503_CR34","doi-asserted-by":"publisher","first-page":"R605","DOI":"10.1186\/bcr1260","volume":"7","author":"G Ursin","year":"2005","unstructured":"Ursin G, Hovanessian-Larsen L, Parisky YR, Pike MC, Wu AH (2005) Greatly increased occurrence of breast cancers in areas of mammographically dense tissue. Breast Cancer Res 7(5):R605\u2013R608. https:\/\/doi.org\/10.1186\/bcr1260","journal-title":"Breast Cancer Res"},{"issue":"1","key":"6503_CR35","doi-asserted-by":"publisher","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead P, Loughrey MB, Fernandez JA, Dombrowski Y, McArt DG, Dunne PD et al (2017) QuPath: open source software for digital pathology image analysis. Sci Rep 7(1):16878. https:\/\/doi.org\/10.1038\/s41598-017-17204-5","journal-title":"Sci Rep"},{"issue":"2","key":"6503_CR36","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jcm.2016.02.012","volume":"15","author":"TK Koo","year":"2016","unstructured":"Koo TK, Li MY (2016) A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chiropr Med 15(2):155\u2013163. https:\/\/doi.org\/10.1016\/j.jcm.2016.02.012","journal-title":"J Chiropr Med"},{"issue":"5","key":"6503_CR37","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.contraception.2017.01.004","volume":"95","author":"P Praditpan","year":"2017","unstructured":"Praditpan P, Hamouie A, Basaraba CN, Nandakumar R, Cremers S, Davis AR, Westhoff CL (2017) Pharmacokinetics of levonorgestrel and ulipristal acetate emergency contraception in women with normal and obese body mass index. Contraception 95(5):464\u2013469. https:\/\/doi.org\/10.1016\/j.contraception.2017.01.004","journal-title":"Contraception"},{"issue":"4","key":"6503_CR38","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.contraception.2016.12.007","volume":"95","author":"CN Basaraba","year":"2017","unstructured":"Basaraba CN, Westhoff CL, Pike MC, Nandakumar R, Cremers S (2017) Estimating systemic exposure to levonorgestrel from an oral contraceptive. Contraception 95(4):398\u2013404. https:\/\/doi.org\/10.1016\/j.contraception.2016.12.007","journal-title":"Contraception"},{"issue":"4","key":"6503_CR39","first-page":"719","volume":"22","author":"N Mantel","year":"1959","unstructured":"Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22(4):719\u2013748","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"6503_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/bjc.1977.1","volume":"35","author":"R Peto","year":"1977","unstructured":"Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV et al (1977) Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer 35(1):1\u201339. https:\/\/doi.org\/10.1038\/bjc.1977.1","journal-title":"Br J Cancer"},{"key":"6503_CR41","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/bjc.1993.111","volume":"67","author":"RB Clarke","year":"1993","unstructured":"Clarke RB, Laidlow IJ, Jones LJ, Howell A, Anderson E (1993) Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status. Br J Cancer 67:606\u2013611. https:\/\/doi.org\/10.1038\/bjc.1993.111","journal-title":"Br J Cancer"},{"key":"6503_CR42","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/cncr.27818","volume":"119","author":"H Iwata","year":"2013","unstructured":"Iwata H, Masuda N, Sagara Y, Kinoshita T, Nakamura S, Yanagita Y et al (2013) Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer. Cancer 119:704\u2013713. https:\/\/doi.org\/10.1002\/cncr.27818","journal-title":"Cancer"},{"key":"6503_CR43","doi-asserted-by":"publisher","first-page":"4559","DOI":"10.1210\/jcem.84.12.6194","volume":"84","author":"LJ Hofseth","year":"1999","unstructured":"Hofseth LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA, Haslam SZ (1999) Hormone replacement therapy with estrogenor estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab 84:4559\u20134565. https:\/\/doi.org\/10.1210\/jcem.84.12.6194","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"6503_CR44","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s12325-020-01555-z","volume":"38","author":"E Ekanem","year":"2021","unstructured":"Ekanem E, Talaulikar V (2021) Medical therapy for fibroids: what next for ulipristal acetate? Adv Ther 38(1):137\u2013148. https:\/\/doi.org\/10.1007\/s12325-020-01555-z","journal-title":"Adv Ther"},{"issue":"5","key":"6503_CR45","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/j.fertnstert.2011.08.021","volume":"96","author":"P Bouchard","year":"2011","unstructured":"Bouchard P, Chabbert-Buffet N, Fauser BC (2011) Selective progesterone receptor modulators in reproductive medicine: pharmacology, clinical efficacy and safety. Fertil Steril 96(5):1175\u20131189. https:\/\/doi.org\/10.1016\/j.fertnstert.2011.08.021","journal-title":"Fertil Steril"},{"issue":"3","key":"6503_CR46","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1210\/clinem\/dgz139","volume":"105","author":"B Small","year":"2020","unstructured":"Small B, Millard CEF, Kisanga EP, Burman A, Anam A, Flannery C et al (2020) The selective progesterone receptor modulator uliprital acetate inhibits the activity of the glucocorticoid receptor. J Clin Endocrinol Metab 105(3):716\u2013734. https:\/\/doi.org\/10.1210\/clinem\/dgz139","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-021-06503-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-021-06503-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-021-06503-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T20:11:37Z","timestamp":1647461497000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-021-06503-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,11]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["6503"],"URL":"https:\/\/doi.org\/10.1007\/s10549-021-06503-1","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,11]]},"assertion":[{"value":"19 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest regarding the publication of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}